- Home
- KBR vs CYTK Comparison
KBR vs CYTK Comparison
Compare KBR & CYTK Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- KBR
- CYTK
- Stock Information
- Founded
- KBR 1901
- CYTK 1997
- Country
- KBR United States
- CYTK United States
- Employees
- KBR N/A
- CYTK N/A
- Industry
- KBR Military/Government/Technical
- CYTK Biotechnology: Pharmaceutical Preparations
- Sector
- KBR Industrials
- CYTK Health Care
- Exchange
- KBR Nasdaq
- CYTK Nasdaq
- Market Cap
- KBR 6.3B
- CYTK 5.6B
- IPO Year
- KBR 2006
- CYTK 2004
- Fundamental
- Price
- KBR $50.51
- CYTK $39.48
- Analyst Decision
- KBR Strong Buy
- CYTK Strong Buy
- Analyst Count
- KBR 8
- CYTK 17
- Target Price
- KBR $71.13
- CYTK $81.63
- AVG Volume (30 Days)
- KBR 1.4M
- CYTK 2.6M
- Earning Date
- KBR 05-06-2025
- CYTK 05-07-2025
- Dividend Yield
- KBR 1.31%
- CYTK N/A
- EPS Growth
- KBR N/A
- CYTK N/A
- EPS
- KBR 2.79
- CYTK N/A
- Revenue
- KBR $7,742,000,000.00
- CYTK $18,474,000.00
- Revenue This Year
- KBR $15.82
- CYTK $55.84
- Revenue Next Year
- KBR $9.28
- CYTK $659.85
- P/E Ratio
- KBR $18.10
- CYTK N/A
- Revenue Growth
- KBR 11.30
- CYTK 145.34
- 52 Week Low
- KBR $43.89
- CYTK $32.74
- 52 Week High
- KBR $72.60
- CYTK $68.76
- Technical
- Relative Strength Index (RSI)
- KBR 50.87
- CYTK 46.41
- Support Level
- KBR $49.67
- CYTK $37.79
- Resistance Level
- KBR $51.01
- CYTK $40.22
- Average True Range (ATR)
- KBR 2.17
- CYTK 3.16
- MACD
- KBR 0.18
- CYTK 0.25
- Stochastic Oscillator
- KBR 66.20
- CYTK 61.55
About KBR KBR Inc.
KBR, formerly Kellogg Brown & Root, is global provider of technology, integrated engineering, procurement, and construction delivery, and operations and maintenance services. The company's business is organized into two segments: government solutions and sustainable technology solutions. KBR has operations in over 30 countries and employs approximately 34,000 people. The firm generated $7.7 billion in revenue in 2024.
About CYTK Cytokinetics Incorporated
Cytokinetics Inc is a biotechnology company that develops muscle biology-driven treatments for diseases characterized by reduced muscle function, muscle weakness, and fatigue. The company develops treatments for diseases such as amyotrophic lateral sclerosis, heart failure, spinal muscular atrophy, and chronic obstructive pulmonary diseases. The treatment is based on small molecules specifically engineered to increase muscle function and contractility. The company is developing muscle-directed investigational medicines that may potentially improve the health span of people with devastating cardiovascular and neuromuscular diseases of impaired muscle function.